bryan johnson

3+ articles

Anti-aging Aravind Srinivas Bryan Johnson Experimental Treatments FDA approval

Tech Millionaire Bryan Johnson Quits Rapamycin: A Controversial Anti-Aging Endeavor

Bryan Johnson, the millionaire tech entrepreneur known for his hefty investments in anti-aging, has stopped using rapamycin after experiencing severe side effects. With the support of Perplexity AI CEO Aravind Srinivas, Johnson's decision has ignited debates on the risks and ethics of experimental longevity treatments.

Jan 17

Tech Millionaire Bryan Johnson Quits Rapamycin: A Controversial Anti-Aging Endeavor

Rapamycin No More: Bryan Johnson Parts Ways with Controversial Anti-Aging Drug

Tech entrepreneur Bryan Johnson, known for his rigorous anti-aging regimen, has decided to stop using the drug rapamycin due to health risks outweighing its potential benefits. Despite facing criticism, Johnson's decision was backed by Aravind Srinivas, CEO of Perplexity AI. This move may significantly impact the anti-aging industry, sparking a shift towards safer alternatives.

Jan 17

Rapamycin No More: Bryan Johnson Parts Ways with Controversial Anti-Aging Drug

Bryan Johnson's Dramatic Rapamycin Exit: A Wake-Up Call for the Anti-Aging Industry!

Tech titan and biohacking fanatic, Bryan Johnson calls it quits on his 5-year rapamycin regimen due to side effects. What does this mean for the anti-aging world? We dive into the potential risks, scientific skepticism, and what the future holds for longevity research.

Jan 17

Bryan Johnson's Dramatic Rapamycin Exit: A Wake-Up Call for the Anti-Aging Industry!